Navigation Links
Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/6/2012

SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2011.

  • Total revenue for the quarter ended December 31, 2011 was $164.9 million, which included net product sales of $160.9 million.
  • Non-GAAP operating income for the quarter ended December 31, 2011 was $17.6 million, compared to a non-GAAP operating income of $22.9 million for the same period in 2010.
  • Full year non-GAAP operating income was $25.7 million, compared to a non-GAAP operating loss of $4.4 million in 2010.
  • Cash, cash equivalents, short-term investments and restricted cash totaled $214.6 million at the end of the quarter.

  • "Our strong execution in 2011 has positioned us to enter 2012 with an extraordinary opportunity to maximize shareholder value. We generated positive operating cash flow, reacquired the full rights to the exenatide franchise, expanded the approved uses for BYETTA, and, most importantly, positioned ourselves well to successfully launch BYDUREON in the U.S. following its recent approval," said Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals. "We will also work to secure a new partner for exenatide outside the U.S. to advance our commitment to diabetes patients around the world, and continue to invest strategically in value-driving opportunities while continuing our focus on financial discipline."

    Highlights of Amylin's Fourth Quarter and Recent Activities

  • Received U.S. Food and Drug Administration (FDA) approval for BYDUREON™ (exenatide extended-release for injectable suspension) – the first and only once-weekly medication approved in the U.S. and the European Union for the treatment of type 2 diabetes. BYDUREON will be available in pharmacies throughout the U.S. later this month.
  • Reacquired exclusive, global rights to develop and commercialize Amylin's exenatide franchise and began discussions with potential partners to develop and commercialize exenatide outside the U.S.
  • Initiated expansion of the Amylin sales force to 715 diabetes sales specialists completely focused on Amylin products with more efficient targeting.
  • Received FDA approval for a new use for BYETTA® (exenatide) injection, making it the only short-acting GLP-1 agonist approved for use as an add-on therapy to insulin glargine, with or without metformin and/or a thiazolidinedione (TZD).
  • Submitted an Investigational New Drug application for AC165198, a new fusion peptide developed under Amylin's collaboration with Biocon, Limited. The first clinical study for this potential therapy for diabetes was initiated in January 2012.

  • Quarter Ended December 31, 2011Net product sales of $160.9 million for the quarter ended December 31, 2011 include $132.6 million for BYETTA and $28.3 million for SYMLIN® (pramlintide acetate) injection. This compares to net product sales of $162.3 million, consisting of $136.4 million for BYETTA and $25.9 million for SYMLIN for the same period in 2010. Revenues under collaborative agreements were $4.1 million for the quarter ended December 31, 2011, compared to $11.9 million for the same period in 2010, which included $10 million in milestone revenue earned upon the launch of BYETTA in Japan.

    Selling, general and administrative expenses increased to $78.3 million for the quarter ended December 31, 2011 from $62.5 million for the same period in 2010. The increase primarily reflects expenses associated with BYDUREON pre-launch activities.  

    Research and development expenses decreased to $27.7 million for the quarter ended December 31, 2011 from $37.5 million for the same period in 2010. The decrease reflects the favorable disposition of certain cost-sharing disputes with Eli Lilly and Company and our ongoing efforts to manage expenses.

    Collaborative profit sharing, which represents Lilly's share of the gross margin for BYETTA, was $43.1 million for the quarter ended December 31, 2011, compared to $63.1 million for the same period in 2010. The decrease is due primarily to the termination of the Lilly collaboration resulting in the termination of gross profit sharing with Lilly in the U.S. effective December 1, 2011.

    Net costs to reacquire economic interest in exenatide products totaled $431.6 million and consist primarily of reacquired marketing rights for unapproved products in the U.S. and are offset by gains associated with the termination of the collaboration with Lilly.  

    Interest and other expense, net, increased to $31.7 million for the quarter ended December 31, 2011 from $8.9 million for the same period in 2010. The increase primarily reflects increased interest expense on the Company's debt, resulting from the promissory note related to the revenue sharing obligation (RSO) entered into in connection with the Settlement Agreement, and a loss on a fair value adjustment to a derivative asset.

    Non-GAAP operating income was $17.6 million for the quarter ended December 31, 2011 compared to $22.9 million for the same period in 2010. GAAP net loss was $461.5 million, or $3.15 per share, for the quarter ended December 31, 2011, compared to GAAP net loss of $19.2 million, or $0.13 per share, for the same period in 2010.

    Year Ended December 31, 2011Total revenues for the twelve months ended December 31, 2011 were $650.7 million. This includes net product sales of $621.6 million, including $517.7 million for BYETTA and $103.9 million for SYMLIN. This compares to net product sales of $651.1 million, consisting of $559.3 million for BYETTA and $91.8 million for SYMLIN for the same period in 2010.

    Revenues under collaborative agreements were $29.1 million for the twelve months ended December 31, 2011, and included a $15.0 million milestone payment from Lilly in connection with the launch of BYDUREON in the European Union in July, compared to $17.7 million for the same period in 2010, which included $10 million in milestone revenue earned upon the launch of BYETTA in Japan.

    Selling, general and administrative expenses decreased to $271.2 million for the twelve months ended December 31, 2011 from $276.9 million for the same period in 2010. The decrease primarily reflects reduced business infrastructure spending resulting from continued efforts to drive efficiencies in the business, offset by higher expenses due to BYDUREON pre-launch activities.

    Research and development expenses decreased to $161.2 million for the twelve months ended December 31, 2011 from $183.1 million for the same period in 2010. The decrease reflects the favorable disposition of certain cost-sharing disputes with Lilly, partially offset by increased spending on our metreleptin lipodystrophy development program.

    Collaborative profit sharing was $222.5 million for the twelve months ended December 31, 2011, compared to $257.1 million for the same period in 2010. The decrease is due to the termination of the Lilly collaboration.

    Interest and other expense, net, increased to $51.9 million for the twelve months ended December 31, 2011 from $25.6 million for the same period in 2010. The increase primarily reflects increased interest expense on the Company's debt, resulting from the promissory note related to the RSO entered into in connection with the Settlement Agreement, and a loss on a fair value adjustment to a derivative asset.

    Non-GAAP operating income was $25.7 million for the twelve months ended December 31, 2011 compared to a non-GAAP operating loss of $4.4 million for the same period in 2010. GAAP net loss for the twelve months ended December 31, 2011 was $543.4 million, or $3.73 per share, compared to GAAP net loss of $152.3 million, or $1.06 per share for the same period in 2010.

    Conference Call Amylin will webcast its Quarterly Update and Year End Conference Call today at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. During the call, the Company plans to provide further details underlying its fourth quarter and full year 2011 financial results. A slide presentation accompanying the conference call is available through the "Investors" section of Amylin's corporate website at www.amylin.com.

    To access the webcast, please log on to www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (800) 857-5738 (U.S./Canada) or (415) 228-4970 (international), participant passcode number 7253303. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (866) 673-3565 (U.S./Canada) or (402) 220-6428 (international).

    Note Regarding Use of Non-GAAP Financial Measures Amylin reports non-GAAP operating income/(loss), non-GAAP net income/(loss) and non-GAAP net income/(loss) per share adjusted for non-cash items and other items such as restructuring charges and charges and credits relating to the reacquisition of exenatide product rights (including amortization and interest expense relating to reacquired assets, fair value adjustments and revenue sharing obligations), which are non-GAAP financial measures. The Company believes that investors' understanding of its progress towards its stated goal of generating sustainable positive non-GAAP operating results is enhanced by this disclosure. In addition, the Company refers to this non-GAAP financial information with its analysis of the Company's financial performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.

    About Amylin PharmaceuticalsAmylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin is committed to delivering novel therapies that transform the way diabetes, obesity and related metabolic disorders are treated. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, Calif., and has a commercial manufacturing facility in Ohio. More information on Amylin Pharmaceuticals is available at www.amylin.com.

    This press release contains forward-looking statements about Amylin, which involve risks and uncertainties. Our actual results could differ materially from those discussed herein due to a number of risks and uncertainties, including risks that BYETTA, SYMLIN or BYDUREON, and the revenues or royalties generated from these products, may be affected by competition, unexpected new data, safety and technical issues, or manufacturing and supply issues; risks that our financial results may fluctuate significantly from period to period and may not meet market expectations; risks that the unaudited financial results set forth in this press release could differ materially from our year-end audited financial results; risks that any financial guidance we provide may not be accurate; risks that our clinical trials will not be completed when planned, may not replicate previous results, may not be predictive of real world use or may not achieve desired end-points; risks that our preclinical studies may not be predictive; risks that our NDAs for product candidates or sNDAs for label expansion requests, may not be submitted timely or receive FDA approval; risks that the launch of BYDUREON will be delayed or unsuccessful; risks that we will not be successful in our efforts to expand the reach of our sales force or in our efforts to secure an exenatide development and commercial partner outside the U.S.; risks that our expense reductions will not be as large as we expect; and other risks inherent in the drug development and commercialization process. Commercial and government reimbursement and pricing decisions and the pace of market acceptance may also affect the potential for BYETTA, SYMLIN or BYDUREON. These and additional risks and uncertainties are described more fully in the Company's recently filed Form 10-Q. Amylin disclaims any obligation to update these forward-looking statements.

    (Financial information to follow)AMYLIN PHARMACEUTICALS, INC.CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share data)(unaudited)Quarter ended
    December 31, Twelve months ended
    December 31, 2011201020112010Revenues:  Net product sales

    $ 160,867$ 162,315$ 621,570$651,113  Revenues under collaborative agreements

    4,06811,87529,10817,700Total revenues

    164,935174,190650,678668,813Costs and expenses:  Cost of goods sold

    12,31814,04248,37661,687  Selling, general and administrative

    78,32362,548271,224276,880  Research and development

    27,67137,510161,215183,083  Collaborative profit sharing

    43,08363,071222,545257,127  Net costs to reacquire economic
    interest in exenatide products

    431,587-431,587-  Restructuring

    1,7077,3287,19016,780Total costs and expenses

    594,689184,4991,142,137795,557Operating loss

    (429,754)(10,309)(491,459)(126,744)Interest and other expense, net

    (31,717)(8,874)(51,940)(25,570)Net loss

    $(461,471)$ (19,183)$(543,399)$(152,314)Net loss per share - basic and diluted

    $ (3.15)$ (0.13)$ (3.73)$ (1.06)Shares used in computing net loss
    per share - basic and diluted

    146,280144,033145,730143,525A reconciliation of reported GAAP operating net loss to non-GAAP operating income (loss) excluding non-cash items is provided in the tables that follow (in thousands, unaudited):Quarter ended
    December 31, Twelve months ended
    December 31, 2011201020112010GAAP operating loss

    $ (429,754)$  (10,309)$ (491,459)$  (126,744) Revenue sharing obligation
      note payments on
      net BYETTA sales (1)

    (6,088)-(6,088)- Stock-based compensation

    9,1948,78832,47236,022 Other non-cash compensation

    3,6134,10416,52719,735 Depreciation and amortization

    10,50714,89247,37357,335 Amortization of deferred revenue and other credits

    (3,141)(1,875)(11,930)(7,500) Net costs to reacquire economic
      interest in exenatide products (1)

    431,587-431,587- Restructuring

    1,7077,3287,19016,780Non-GAAP operating income (loss)

    $  17,625$
    22,928$   25,672$   (4,372)Quarter endedDecember 31,Twelve months endedDecember 31,2011201020112010GAAP net loss

    $ (461,471)$  (19,183)$ (543,399)$  (152,314) Revenue sharing obligation note payments on  net BYETTA sales (1)

    (6,088)-(6,088)- Stock-based compensation

    9,1948,78832,47236,022 Other non-cash compensation

    3,6134,10416,52719,735 Depreciation and amortization

    10,50715,41747,37357,335 Amortization of deferred revenueand other credits

    (3,141)(2,400)(11,930)(7,500) Net costs to reacquire economic
    interest in exenatide products (1)

    431,587-431,587- Restructuring

    1,7077,3287,19016,780Interest expense, net

    11,7634,65823,9789,002Loss on fair value adjustments

    15,751-15,751-Non-GAAP net income (loss)

    $  13,422$
    8,712$   13,461$   (20,940)Non-GAAP net income (loss) per shareBasic

    $ 0.09$ 0.13$ 0.09$  (0.15)Diluted

    $ 0.09$ 0.13$ 0.09$  (0.15)Shares used in per share calculationsBasic

    146,280144,033145,730143,525Diluted

    146,778144,926146,274143,525(1) With the termination of the Lilly collaboration we have revised our non-GAAP presentation to exclude charges and credits relating to the reacquisition of the exenatide product rights, including amortization and interest expense relating to reacquired assets, and have added a new item to reflect an adjustment to GAAP operating loss for the payments we are required to make to Lilly for the promissory note related to the revenue sharing obligation, or 15% of net exenatide sales.AMYLIN PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)December 31,December 31,20112010(unaudited)AssetsCash, cash equivalents and short-term investments

    $204,065

    $442,663Restricted cash

    10,519

    15,000Accounts receivable, net

    45,489

    54,645Inventories, net

    111,959

    118,629Other current assets

    49,158

    45,458Property and equipment, net

    831,162

    811,745Intangible and other assets related
    to economic rights reacquired or to be reacquired

    601,539

    -Other assets

    16,308

    43,289Total assets

    $1,870,199

    $1,531,429Liabilities and stockholders' equity Current liabilities

    296,017

    401,595Other liabilities, net of current portion

    292,584

    317,654Promissory note related to revenue sharing
    obligation, net of current portion

    924,306

    -Long-term debt

    496,037

    468,697Stockholders' (deficit)/equity

    (138,745)

    343,483Total liabilities and stockholders' (deficit)/equity

    $1,870,199

    $1,531,429
    '/>"/>

    SOURCE Amylin Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
    2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
    3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
    4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
    5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
    6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
    7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
    8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
    9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
    10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
    11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/5/2016)... 5, 2016 Amgen (NASDAQ: AMGN ) will ... Healthcare Conference at 9:15 a.m. ET on Wednesday, Feb. 10, ... David W. Meline , executive vice president and chief financial ... of the presentation can be accessed from the Events Calendar ... of the webcast will also be available on Amgen,s website ...
    (Date:2/5/2016)... Feb. 5, 2016  ivWatch, a medical devices company, is ... Award granted by Governor Terry McAuliffe,s office. ivWatch ... February 25th at an event to be held at the ... award honors professionals and business that have made significant contributions ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
    (Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ("Aralez") ... POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following ... shareholders of Tribute. The combined company will operate under ... with operations in Canada , ... States . Under the terms of the Agreement ...
    Breaking Medicine Technology:
    (Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Today, the ... , announced that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian ... TV Network. , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis ...
    (Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD ... in their Napa Valley office. The technique utilizes the body’s own healing abilities ... and Dr. Furnas, are part of only a select few cosmetic surgeons bringing ...
    (Date:2/5/2016)... ... February 05, 2016 , ... The Lymphoma ... innovative lymphoma research and serving the lymphoma community through a comprehensive series of ... host, Swirl, A Wine Tasting Event at the La Gorce Country Club in ...
    (Date:2/5/2016)... ... 2016 , ... Regular gym users know the routine: each January, they see ... the treadmills. It’s a predictable trend. After the excesses of November and December, people ... by joining gyms, starting new walking or running routines, or signing up for Zumba. ...
    (Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
    Breaking Medicine News(10 mins):